spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  pneumococcal conjugate vaccine 

 HSMN NewsFeed - 4 May 2020
SutroVax Appoints Andrew Guggenhime as Chief Financial Officer and Chief Business Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Mar 2020
SutroVax Announces $110M Series D Financing to Advance Broadest-Spectrum Pneumococcal Vaccine Candidates to Prevent Pneumonia
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 30 Jan 2020
SutroVax Announces Executive Appointment
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Jan 2019
SutroVax Announces Executive Appointments
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Jun 2018
SutroVax Announces $85M Series C Financing led by TPG Growth
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 11 Oct 2017
SutroVax Appoints Veteran Vaccine Experts to Executive Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Jul 2017
Dr. Moncef Slaoui, former GlaxoSmithKline Chairman of Vaccines, Appointed to SutroVax Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Mar 2017
SutroVax Announces Closing of $64M via Series B Financing
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 12 Mar 2014
Pfizer Presents Detailed Results From Landmark Community-Acquired Pneumonia Immunization Trial In Adults (CAPiTA) Evaluating Efficacy Of Prevenar 13*
Biopharmaceuticals
 HSMN NewsFeed - 17 Oct 2013
Pfizer Receives European Approval For Label Update Regarding The Use Of Prevenar 13 In Certain High-Risk Populations
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 16 Dec 2011
Pfizer Broadens and Extends Commitment to Help Prevent Pneumococcal Disease in Infants and Young Children in the World’s Poorest Countries
Biopharmaceuticals
 HSMN NewsFeed - 27 Oct 2011
Pfizer Receives European Approval to Extend Use of Prevenar 13 to Adults 50 Years and Older for the Prevention of Invasive Pneumococcal Disease
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 24 Feb 2010
Pfizer Receives FDA Approval for Prevnar 13 for the Prevention of Invasive Pneumococcal Disease in Infants and Young Children
Biopharmaceuticals FDA
 HSMN NewsFeed - 30 Dec 2009
Pfizer Provides U.S. Regulatory Update On Prevnar 13 Vaccine
Biopharmaceuticals FDA
 HSMN NewsFeed - 14 May 2008
New Data Support Routine Childhood Vaccination With PREVENAR in Europe
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 1

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 1 additional stories matching:
pneumococcal conjugate vaccine
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.